Physician profile

Sharae Johnson

Obstetrics & Gynecology · Beaumont, TX

NPI 1164862512

$422.75

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$146.57

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $187.91 2019-2023
Ethicon US, LLC $73.28 2023 Enseal
Hologic Sales and Service, LLC $43.65 2023-2024 Aptima
Avion Pharmaceuticals $31.04 2022-2023 Balcoltra
Myovant Sciences INC. $18.88 2022
Organon LLC $18.11 2022
Pfizer INC. $17.44 2022
Spr Therapeutics, INC $16.50 2019
Merck Sharp & Dohme LLC $15.94 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sharae Johnson

$422.75

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/425139/sharae-johnson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.